This exosome‐assisted delivery strategy rescues the potency of exogenous STING agonists (Figure 1b) to enhance antigen‐presentation performance within DCs and subsequent tumor‐specific T‐cell immunoresponse. The gene discussed is STING1; the disease is neoplasm.